At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Market Closed 11-01 16:00:00 EDT
1.01
+0.01
+1.00%
盘后1.00
-0.01-0.96%
17:56 EDT
High1.02
Low0.9770
Vol37.66K
Open0.9990
D1 Closing1.00
Amplitude4.30%
Mkt Cap6.47M
Tradable Cap6.35M
Total Shares6.41M
T/O37.60K
T/O Rate0.60%
Tradable Shares6.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.